Briefcase Email Alerts Downloads Snapshot RSS Email Printed Materials Print this page

Achieve

Press Releases


 
Press Releases
  Date Title and Summary View
Jan 27, 2017
LA JOLLA, Calif., Jan. 27, 2017 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it received written communication from the U.S. Food and Drug Administration (FDA) that the clinical development program for RG-...
Dec 6, 2016
LA JOLLA, Calif., Dec. 6, 2016 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced two new drug development candidates at its R&D day, held in New York. The first candidate, RGLS5040, is an anti-miR targeting microRNA...
Nov 22, 2016
LA JOLLA, Calif., Nov. 22, 2016 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it will host a R&D day on Tuesday, December 6, 2016 from 8:30 a.m. to 11:30 a.m. EST in New York City where it plans to announce...
Nov 1, 2016
LA JOLLA, Calif., Nov. 1, 2016 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported financial results for the three and nine months ended September 30, 2016 and provided a summary of corporate highlights.   "...
Oct 25, 2016
LA JOLLA, Calif., Oct. 25, 2016 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced it will release third quarter financial results on Tuesday, November 1, 2016 after the market closes. Regulus will host a ...
Oct 6, 2016
LA JOLLA, Calif., Oct. 6, 2016 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced the grant of an inducement stock option to Timothy M. Wright, M.D. on October 3, 2016 in connection with his appointment as Regulus' C...
Oct 5, 2016
LA JOLLA, Calif., Oct. 5, 2016 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced the appointment of Timothy M. Wright, M.D. as Chief Research and Development (R&D) Officer reporting to Paul Grint, M.D., President an...
Aug 31, 2016
LA JOLLA, Calif., Aug. 31, 2016 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Paul C. Grint, M.D., President and Chief Executive Officer of Regulus, will present a company overview at the 2016 Wells Fargo H...
Aug 9, 2016
LA JOLLA, Calif., Aug. 9, 2016 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Joseph "Jay" Hagan, Chief Operating Officer of Regulus, will present a company overview at the 2016 Wedbush PacGrow Healthcare Co...
Aug 2, 2016
LA JOLLA, Calif., Aug. 2, 2016 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported financial results for the three and six months ended June 30, 2016 and provided a summary of corporate highlights. "The seco...
Page: FirstPrevious
2
... NextLast
= add release to Briefcase